Protective effect of nicotine on lipopolysaccharide-induced acute lung injury in mice

Respiration. 2011;81(1):39-46. doi: 10.1159/000319151. Epub 2010 Jul 21.

Abstract

Background: Recently, nicotine administration has been shown to be a potent inhibitor of a variety of innate immune responses, including endotoxin-induced sepsis.

Objective: It was the aim of this study to evaluate the effect of nicotine on attenuating lung injury and improving the survival in mice with lipopolysaccharide (LPS)-induced acute lung injury (ALI).

Methods: ALI was induced in mice by intratracheal instillation of LPS (3 mg/ml). The mice received intratracheal instillation of nicotine (50, 250 and 500 μg/kg) before or after LPS administration. Pulmonary histological changes were evaluated by hematoxylin-eosin stain, and lung wet/dry weight ratios were observed. Concentrations of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and high mobility group box (HMGB)-1, as well as myeloperoxidase (MPO) activity were measured by enzyme-linked immunosorbent assay. The mortality rate was recorded and analyzed by the Kaplan-Meier method.

Results: Nicotine pretreatment significantly attenuated the severity of lung injury and inhibited the production of TNF-α, IL-1β and HMGB-1 in mice with ALI. After LPS administration, the lung wet/dry weight ratios, as an index of lung edema, and MPO activity were also markedly reduced by nicotine pretreatment. Early treatment with a high dose of nicotine (500 μg/kg) after LPS administration decreased the mortality in mice with ALI, even when treatment was started 24 h after LPS administration.

Conclusion: Nicotine attenuated the lung injury and reduced mortality in mice with LPS-induced ALI.

MeSH terms

  • Acute Lung Injury / chemically induced
  • Acute Lung Injury / immunology
  • Acute Lung Injury / mortality
  • Acute Lung Injury / therapy*
  • Animals
  • Disease Models, Animal
  • Drug Administration Schedule
  • Drug Dosage Calculations
  • Escherichia coli*
  • HMGB1 Protein / immunology
  • Instillation, Drug
  • Interleukin-1beta / immunology
  • Kaplan-Meier Estimate
  • Lipopolysaccharides* / administration & dosage
  • Lipopolysaccharides* / adverse effects
  • Lipopolysaccharides* / immunology
  • Lung / immunology
  • Lung / pathology
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Nicotine / immunology
  • Nicotine / therapeutic use*
  • Peroxidase / metabolism
  • Protective Agents
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • HMGB1 Protein
  • Interleukin-1beta
  • Lipopolysaccharides
  • Protective Agents
  • Tumor Necrosis Factor-alpha
  • Nicotine
  • Peroxidase